Cáncer de PróstataMás opciones en Pruebas de AEP

Cada año se diagnostican aproximadamente 700,000 casos nuevos de cáncer de próstata en el mundo entero, y aproximadamente 221,000 muertes ocurren anualmente debido a este tipo de cáncer. Siemens Healthcare Diagnostics ofrece un menú completo de pruebas de Antígeno Específico de Próstata (AEP) que le ayudan en la detección, monitoreo y gestión del cáncer de próstata. Además de las pruebas de AEP tradicionales, el portafolio de los análisis de AEP de Siemens incluye ensayos únicos de AEP complejo y AEP de Tercera Generación que son alternativas a las pruebas convencionales.

Laboratorians

Siemens can equip your cancer center, hospital, or reference laboratory with the full menu of in vitro PSA tests demanded by today’s healthcare professionals, including Complexed PSA and 3rd Generation PSA assays that are alternatives to traditional PSA tests. The Siemens portfolio of PSA assays provides your healthcare clients with more choices to aid in prostate cancer detection, monitoring, and follow-up.
 

The Siemens Portfolio of PSA Assays

PSA tests run on ADVIA Centaur®, IMMULITE® and Dimension® systems ensure cost-effectiveness and fast turnaround times.
 

PSA

PSA

PSA

PSA

PSA

PSA

PSA

fPSA1

fPSA

fPSA

fPSA

fPSA

fPSA

fPSA

Complexed PSA

Complexed PSA

Third Generation PSA


-

-

-

PSA Test

PSA testing is clinically accepted by the NACB and EGTM for both detection and monitoring.1

  • Quantitatively measures prostate specific antigen in serum
  • Classic screening method to aid in the detection of prostate cancer
  • Used in conjunction with a digital rectal examination (DRE)

 

3rd Generation PSA Test2

Our 3rd Generation PSA assay aids in the detection of prostate cancer and is used as an adjunctive test to aid in the management of prostate cancer patients.

  • Provides information on possible relapse in facilitating patient management
  • Provides an early indication of disease status after treatment when used in conjunction with other clinical information3
  • Approved for prostate cancer detection in conjunction with a digital rectal examination (DRE)

 

Free PSA Test

Our fPSA assay helps guide decision-making in men aged 50 years or older who have DRE findings not suspicious of cancer who are in the diagnostic gray zone (4.0–10 ng/mL).

  • Percent free PSA assessment may help to reduce unnecessary biopsies4,5
  • It helps to differentiate cancer from benign prostatic hyperplasia
  • Percent free PSA is lower in prostate cancer than in benign prostate hyperplasia4,5

 

Complexed PSA Test

The Siemens proprietary Complexed PSA is an alternative to traditional PSA testing for frontline detection.

  • PSA complexed with alpha-1-antichymotrypsin (ACT) comprises a higher proportion of PSA in men with prostate cancer6-8
  • It is recommended as a frontline detection test
  • It is used in conjunction with a digital rectal examination (DRE)
     

System

Assay

Reportable Range

PSA

0.01 ng/mL - 100 ng/mL

 

Complexed PSA

0.03 ng/mL - 100 ng/mL

 

FPSA*

0.01 ng/mL - 25 ng/mL

PSA

0.04 ng/mL - 150 ng/mL

 

FPSA

0.07 ng/mL - 25 ng/mL

 

3rd Generation PSA**

0.005 ng/mL - 20 ng/mL

PSA

0.13 ng/mL - 100 ng/mL

 

FPSA

0.06 ng/mL - 45 ng/mL

PSA

0.010 ng/mL - 100 ng/mL

 

FPSA

0.015 ng/mL - 20 ng/mL

1. NACB Laboratory Medicine Practice Guidelines. Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. 2009.
2. The IMMULITE Third Generation PSA assay has not been evaluated and approved by the FDA for use with the IMMULITE Free PSA assay in the percent free PSA calculations.
3. Shen, et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J of Urol 2005; 173; 777-780.
4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7.
5. Lilja, et al. Significance of different molecular forms of serum PSA. Urol C Clin North Am 1993; 20:681:686.
6. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek D J,Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 2000 Nov;164(5):1671-2.
7. Lilja H, Christtensson A, Matikainen M-T, et al. Prostate-specific antigen occurs predominantly in complex alpha-1-antichymotrypsin. Clin Chem 1991 ; 7 :1618-25.
8. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.